SPHRF News and Press, Starpharma Holdings Ltd

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

2023-07-27 09:40:36 ET Summary The news on Starpharma share price is challenging as a significant shareholder exits. The news of commercially interesting developments continues to broaden, meaning that substantial share price upside seems likely. Starpharma has a strong board ...

(NewsDirect) Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) CEO Dr Jackie Fairley speaks with Proactive from the ASX Small and Mid-Cap Conference March 2023. The company is focused on the development of pharmaceutical and medical products for unmet patient needs, including in the areas ...

Summary AstraZeneca plans to grow beyond 2025 by building its innovation pipeline. Investors in the target benefit when a big pharma company acquires an emerging company. Starpharma is an example of a company that might be of interest to a big pharma acquirer. Rarely, emer...

The treatment window for COVID is very narrow; this limits the value of even effective treatments. Molnupiravir effectiveness ~30%; Paxlovid seems more effective in trials, but the real world awaits. Molnupiravir is not transforming for Merck, but Paxlovid at worst means a major b...

Molnupiravir results are striking for very early treatment, but this doesn't compare with vaccination; the time window for effect is short and the trial was mostly with unvaccinated people. Merck has a Phase 3 trial testing if molnupiravir can prevent infection of a person exposed to ...

The delta variant of SARS-CoV-2 is changing the rules of engagement because it is highly infectious and it gets passed on rapidly. Scientific discoveries help explain why antivirals are ineffective and why nasal treatment looks powerful. Once the virus gets started in a sensitive indi...

Merck/Ridgeback Bio partnership on tablet form of antiviral molnuparivir attracts US Government interest for early-stage COVID treatment. Starpharma’s Viraleze for prevention and early-stage COVID treatment as a nasal spray gets traction in Europe and India. Monoclonal anti...

Starpharma rises on a partnership with Merck on DEP-Antibody Drug Conjugates. AstraZeneca AZD0466 (with Starpharma DEP technology) Phase 1 trial goes global. Viraleze, registered in Europe and positioned as a COVID preventative/early treatment, stable at room temperature and compa...

Pfizer sees $15 billion revenue from the Pfizer/BioNTech COVID vaccine in 2021 and it could completely change Pfizer’s revenue and earnings trajectory. Think about what this will do for BioNTech. The above revenues are for the “pandemic phase.” Pfizer/BioNTech may...